As an independent biopharmaceutical company of the Intas Group, the company has fully integrated biopharmaceutical operations with R&D facility and an EU-GMP certified bio-pharmaceutical manufacturing facility.
Intas Biopharma is also actively pursuing the Contract Research and Manufacturing Services(CRAMS) line of business. To expand its CRAMS business, Intas Biopharmaceuticals Ltd., in June 2008, acquired a US biotechnology corporation, Biologics Process Development Incorporated (BPD), based in Poway, California.
The biotechnology division was demerged as an independent company Intas Biopharmaceutcials Ltd. in Sep 2006. The ownership remained with the Chudgar family.
Kotak Private Equity Group invested $10 Million equity in the company in late 2007. Till that time company had invested Rupees 1 billion ($25 Million) in its facility.
The company faced EU-GMP (Good manufacturing practice) audit in Dec 2006, in order to seek approval of clinical trial of its biosimilar Filgrastim in Europe and was certified as EU-GMP compliant in April 2007, becoming the first company in India to receive such certification for biologics facility.
Intas Biopharma has focused on biosimilars and has generic version of 3 of the top 10 blockbuster in its product basket. It launched its first product Neukine injection (Filgrastim)/ GCSF in July 2004.
Erythropoietin injection under the brand name of Erykine, for anemia due to critical illness like chemotherapy,was introduced in Aug 2005 and Interferon α2b under the brand name of Intalfa was launched in April 2007.
Intas Biopharma also considers itself first company in the world after the innovator, to introduce Pegylated version of GCSF (PEG-GCSF,under the brand name of Neupeg. Neupeg was launched in Aug 2007. The PEG (polyethylene glycol) form has a much longer half-life, reducing the necessity of daily injections.
Kwizda, Austria and Intas Biopharmaceuticals Ltd. jointly completed phase I clinical trial study of Neukine, biosimilar form of recombinant GCSF in April 2008, paving way towards start of Phase III Clinical trials in Europe.The study was a single-dose, randomised, double blind, two-way crossover trial and used an active control. With this study, Intas Biopharmaceuticals became first Indian company to enter the regulated biotherapeutic market.
Intas Biopharmaceuticals Ltd signed an agreement with Canadian drug major Apotex Inc, in May 2008, to co-develop and market the low-cost version of a biotech cancer medicine filgrastim (G-CSF) in North America and Europe.
Intas Biopharmaceuticals Ltd., of Ahmedabad, India, acquired Biologics Process Development Inc., of Poway, Calif.(Other News To Note)
Jun 25, 2008; Intas Biopharmaceuticals Ltd., of Ahmedabad, India, acquired Biologics Process Development Inc., of Poway, Calif. With the...
WIPO ASSIGNS PATENT TO INTAS BIOPHARMACEUTICALS FOR "LIQUID FORMULATION OF FOLLICLE STIMULATING HORMONE" (INDIAN INVENTORS)
Aug 20, 2011; GENEVA, Aug. 20 -- Publication No. WO/2011/099036 was published on Aug. 18. Title of the invention: "LIQUID FORMULATION OF...
WIPO ASSIGNS PATENT TO INTAS BIOPHARMACEUTICALS FOR "A THERMOSTABLE LIQUID FORMULATION OF GONADOTROPINS" (INDIAN INVENTORS)
Sep 12, 2011; GENEVA, Sept. 12 -- Publication No. WO/2011/108010 was published on Sept. 09. Title of the invention: "A THERMOSTABLE LIQUID...
WIPO PUBLISHES PATENT OF INTAS BIOPHARMACEUTICALS FOR "LIQUID FORMULATION OF POLYPEPTIDES CONTAINING AN FC DOMAIN OF AN IMMUNOGLOBULIN" (INDIAN INVENTORS)
Nov 23, 2011; GENEVA, Nov. 21 -- Publication No. WO/2011/141926 was published on Nov. 17. Title of the invention: "LIQUID FORMULATION OF...
Viropro Inc., of Montreal, and Intas Biopharmaceuticals Ltd., of Ahmedabad, India, signed a memorandum of understanding for the production of an undisclosed therapeutic protein.(Other News To Note)
May 16, 2007; * Viropro Inc., of Montreal, and Intas Biopharmaceuticals Ltd., of Ahmedabad, India, signed a memorandum of understanding for the...